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ccRCCThyroid hormone receptor β1 (TRβ1) is a hormone-dependent transcription factor activated by 3,5,3'-L-
triiodothyronine (T3). TRβ1 functions as a tumor suppressor and disturbances of the THRB gene are frequent
ﬁndings in cancer. Translational control mediated by untranslated regions (UTRs) regulates cell proliferation,
metabolism and responses to cellular stress, processes that are involved in carcinogenesis. We hypothesized
that reduced TRβ1 expression in clear cell renal cell cancer (ccRCC) results from regulatory effects of TRβ1 5′
and 3′UTRs on protein translation. We determined TRβ1 expression and alternative splicing of TRβ1 5′ and 3′
UTRs in ccRCC and control tissue together with expression of the type 1 deiodinase enzyme (coded by DIO1, a
TRβ1 target gene). Tissue concentrations of T3 (which are generated in part by D1) and expression of
miRNA-204 (an mRNA inhibitor for which a putative interaction site was identiﬁed in the TRβ1 3′UTR) were
also determined. TRβ1 mRNA and protein levels were reduced by 70% and 91% in ccRCC and accompanied by
absent D1 protein, a 58% reduction in tissue T3 concentration and 2-fold increase in miRNA-204. Structural
analysis of TRβ1 UTR variants indicated that reduced TRβ1 expression may be maintained in ccRCC by
posttranscriptional mechanisms involving 5′UTRs and miRNA-204. The tumor suppressor activity of TRβ1
indicates that reduced TRβ1 expression and tissue hypothyroidism in ccRCC tumors is likely to be involved in
the process of carcinogenesis or in maintaining a proliferative advantage to malignant cells.G.R. Williams),
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
The thyroid hormones, T3 (3,5,3′-L-triiodothyronine) and T4
(thyroxine), regulate key cellular processes including differentiation,
proliferation, apoptosis and metabolism. Thyroid hormone action is
mediated via the thyroid hormone receptors TRα1 and β1, which are
expressed widely and act as T3-inducible transcription factors [1]. TRs
bind speciﬁc thyroid hormone response elements (TREs) in T3
responsive genes and regulate expression of target genes including
oncogenes [2] and tumor suppressors [3]. Human THRB gene contains
10 exons (Fig. 1A) with an open reading frame extending from exon 3
to exon 10. Previous studies indicate that TRβ1 expression is
perturbed in tumors, including clear cell renal cell cancer (ccRCC)
[4]. Several mechanisms have been proposed to contribute to reduced
TRβ1 expression in cancer cells. Examples include hypermethylation
of the TRβ1 promoter and loss of heterozygosity (LOH) at the THRBlocus [5] and mutations found in TRβ1 transcripts [6]. Although all
these mechanisms may lead to reduced transcript expression,
aberrant TRβ1 mRNA expression correlates poorly with protein
expression in ccRCC [4], suggesting that TRβ1 translation in human
renal carcinomas may involve post-transcriptional regulation.
The ﬁnal concentration of expressed protein depends on its
translation efﬁciency and stability. Since initiation of translation is a
rate-limiting step [7], factors inﬂuencing this process limit the
efﬁciency of protein synthesis. Translation initiation events are
controlled by secondary structures of UnTranslated Regions (UTRs)
within mRNAs. The UTRs contain cis-acting sequences recognized by
trans-acting factors including translation initiation and elongation
factors and microRNAs [8]. Alternative splicing of the TRβ1 mRNA 5′
UTR results in expression of multiple 5′UTR variants [9,10]. Expression
of these variants is tissue-speciﬁc, and previous studies indicated they
differentially regulate the efﬁciency of protein translation [10].
Similarly, cis-acting elements in the 3′UTR of TRβ1 may inﬂuence
the efﬁciency of protein translation [11].
It is well known that UTRs can be involved in carcinogenesis. For
instance, mammary gland BRCA1 suppressor is characterized by a
short, efﬁciently translated 5′UTR variant. In some breast cancers the
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upstream open reading frames (uORFs) resulting in reduced BRCA1
protein synthesis [12]. Moreover, tumor cells expressing a shorter,
readily translated variant of the retinoic acid receptor RARβ2 5′UTR
exhibited greater sensitivity to retinoic acid in comparison to cells
expressing a longer 5′UTR variant less efﬁciently translated [13,14].
Although the protein coding region of TRβ1 has been extensively
investigated in various tumor cell types, there is little information
regarding UTR-dependent control of the efﬁciency of TRβ1 transla-
tion. In these studies we hypothesized that aberrant TRβ1 protein
expression in ccRCC results from reduced levels of TRβ1 mRNA,
alternative splicing of 5′ and 3′UTR TRβ1 mRNA and altered
expression of miRNAs that regulate TRβ1 translation. To address
these possibilities we characterized TRβ1 mRNA and protein
expression and alternative splicing of TRβ1 UTRs in ccRCC and control
tissue as well as the levels of the type 1 deiodinase enzyme (D1, a
TRβ1 target gene) and the tissue concentrations of T3 and T4, which
are regulated by activity of the D1 enzyme. Finally, we investigated
the possible role of mRNA UTRs in the control of TRβ1 protein
translation.
2. Materials and methods
2.1. Tissue samples
Tissue samples were obtained from nephrectomies performed on
patients with clear cell renal cell cancer (n=39) or non-neoplastic
abnormalities (nephrolithiasis, hydronephrosis, injury, n=10) under
permission of the Ethical Committee of Human Studies (The Medical
Centre of Postgraduate Education). Samples were divided into three
groups: cancer tissue (n=39, T) and two control tissues: paired
normal tissue from the opposite pole of the malignant kidney with no
histological evidence of tumor (n=39, C) and tissue from kidney
removed for non-neoplastic disease (n=10, N). The aim of using
controls “N”was to clearly separate cancer-speciﬁc molecular changes
from those resulting from non-cancerous pathologies. Clear cell renal
cell cancer was diagnosed according to WHO criteria [15].
2.2. Plasmids and transient transfection assays
TRβ1 5′UTR variants A-G pGL3 constructs were described
previously [10] pGL3-F1 was constructed using HindIII/NcoI cloning
of PCR ampliﬁed F1 variant (primers p1d1F and pex3R-PscI,
Supplementary Data Table 3).
Caki-2 cells (clear cell renal cell cancer, American Type Culture
Collection, Manassas, VA) were seeded at 5×105 cells per well and
after 24 h were transfectedwith 100 ng pRL-TK and 1 μg of pGL-5′UTR
vectors, using 1 μg/μl PEI (Linear Polyethylenimine, Cat. No. 23966-2,
Polysciences Inc., Warrington, PA) and 150 mM NaCl in FBS-free
McCoy's medium (Gibco/Invitrogen, Carlsbad, Ca). Five hours after
transfection, the medium was replaced with medium plus 10% FBS
(Sigma-Aldrich, Saint Louis, MO) and penicillin–streptomycin solu-
tion (Sigma-Aldrich, Saint Louis, MO). Cells were grown for 24 hrs at
37 °C in 5% CO2 and harvested for dual-luciferase assay (Promega,
Madison, WI) using a Synergy2 luminometer (BioTek, Winooski, VT).
All transfections and luciferase assays were performed in triplicate.
For transfection with miRNA precursors, Caki-2 cells were plated
at 5×105 cells per 12-well dish and transfected 24 h later usingFig. 1. Human THRB gene. A. THRB gene (Ref.seq.:NC_000003.11: 378609 bp region of chrom
(NP_000452.2). Exons are numbered 1–10 and sized above. Amino acid positions below the
in TRβ1 protein. B. Previously published (A-IVS4A) [10] and newly identiﬁed (A2-IVS4B) sp
published (3′UTR-1) and newly identiﬁed (3′UTR-2) splice variant of TRβ1 3′UTR that lacks
underlined). Primers are indicated by arrows.Lipofectamine 2000 reagent (Invitrogen, Carlsbad, Ca) following
manufacturer's protocol. Each transfection reaction contained
37.5 nM of precursor miRNA-204 (PremiR™ miRNA Precursor
Molecule, Ambion, Foster City, CA). As control, transfection with
scrambled microRNA (Negative microRNA Control, Ambion, Foster
City, CA) was performed. Cells were harvested 48 h after transfection
for total RNA isolation for real-time RT-PCR and 72 h after transfection
for protein isolation.
Coupled in vitro transcription and translation assay: In vitro protein
synthesis was performed from pKS derived plasmids: UTR_A+Luc,
TRβ1 ORF+Luc, UTR_A+TRβ1 ORF+Luc and Control plasmid. Control
plasmid was constructed by cloning LUC gene downstream of the T7
promoter in pKS vector [10] and served as a basis for construction of
other plasmids used in the study: (1) UTR_A+Luc (THRBUTR-A cloned
upstream of luciferase in pKS vector), TRβ1 ORF+Luc (TRβ1 ORF
cloned upstream of luciferase in pKS vector), UTR_A+TRβ1 ORF+Luc
(5′UTR A inserted upstream of TRβ1ORF and luciferase reporter gene).
Reaction was conducted in RTS 100 Wheat Germ CRCF system (Roche
Diagnostics, Mannheim, Germany) in conditions recommended by the
manufacturer, using 2 μg of each plasmid.
2.3. RNA and miRNA isolation and reverse transcription
RNAs were isolated from ~100 mg of frozen tissue using
GeneMATRIX Universal RNA Puriﬁcation Kit (EURx, Gdansk, Poland)
or mirPremier microRNA Isolation Kit (Sigma-Aldrich, St. Louis, MO).
Reverse transcription was performed using RevertAidTM H Minus
First Strand cDNA Synthesis Kit (Fermentas, Vilnius, Lithuania) and
200 ng total RNAwith RandomHexamer primers, or 30 ngmiRNA and
speciﬁc stem-loop primers with 5′-overhangs (Supplementary Data,
Table 1).
2.4. Real-time PCR
Quantitative real-time PCR of UTRs was performed using Quanti-
Fast SYBR Green PCR Kit (Qiagen, Hilden, Germany) under conditions:
95 °C, 5 min; 50 cycles: 95 °C, 10 s, 60 °C, 30 s; melting curve analysis:
135 cycles: 50 °C; 0.3 °C increase in each cycle. Ct data were acquired
after reaching the threshold in real-time module, usually between 18
and 36 cycle; cycle efﬁciency was corrected using iQ5 thermocycler
software (Bio-Rad, Hercules, CA). Quantitation of transcripts was
determined using serial dilutions of a known number of DNA
amplicons and normalized to expression of endogenous ACTB1.
Semi-quantitative real-time PCR of DIO1 was performed using
SYBR Green I Master (Roche Diagnostics, Mannheim, Germany) under
conditions: 95 °C for 10 min; 3 cycles: 95 °C, 30 s; 61 °C, 30 s; 72 °C,
30 s; 50 cycles: 95 °C, 20 s; 57 °C, 30 s; 72 °C, 30 s, 68 °C, 15 s
(acquisition); melting curve analysis 120 cycles: 58 °C; 0.3 °C increase
in each cycle. Results were normalized to expression of ACTB1.
Real-time PCR quantitation of miRNAs was performed using
QuantiFast SYBR Green PCR Kit (Qiagen, Hilden, Germany) and
universal primer UniAmpHindIII with sequence homology to over-
hangs of primers used in reverse transcription and miRNA-speciﬁc
primers. The conditions used were: initial denaturation: 95 °C, 5 min.,
32 cycles: denaturation 95 °C, 11 s, annealing 52 °C, 11 s, and
extension 65 °C, 30 s; followed by melting curve analysis: 81 cycles:
55 °C with 0.5 °C temperature increase in each cycle. For normaliza-
tion of miRNA expression, U6 snRNA [16] was used as an internalosome 3 from base 24133709 to 24512317), TRβ1 mRNA (NM_000461.4) and protein
protein demonstrate boundaries of the DNA and ligand binding domains (DBD and LBD)
lice variants of TRβ1 mRNA 5′UTR. Exons are labeled 1a–1e, 2a–2c and 3. C. Previously
the 61 bp region shown, which contains a potential binding site for miRNA-204 (bold
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Fig. 2. Expression of TRβ1 mRNA and protein in ccRCC. A. Expression of TRβ1 mRNA
containing the TRβ1 protein ORF. T: ccRCC tissue, C: paired normal control tissue from
ccRCC kidneys, N: non-neoplastic kidney. The data aremeans±S.E. (n=10 forN,n=39
for C, n=39 for T). B. Expression of TRβ1 protein. Upper panel: Western blot showing
expression of TRβ1 (52 kDa protein) andβ-actin (42 kDa protein) in four representative
C and T paired samples. Lower panel: mean TRβ1 expression in paired samples C and T
normalized to β-actin (n=11 for C, n=11 for T). The data are means±S.E. Statistical
analysis was performed using paired t-test to compare C and T. *pb0.05.
998 A. Master et al. / Biochimica et Biophysica Acta 1802 (2010) 995–1005control. Relative miRNA expression was calculated using the 2−ΔCt
method [53].
Primer sequences (Biote21, Krakow, Poland) for all real-time PCR
reactions are shown in Supplementary Data, Tables 1–2.
2.5. Identiﬁcation of THRB UTR splice variants
5′UTR variants were ampliﬁed using Perpetual OptiTaq Polymer-
ase (EURx, Gdansk, Poland), 8 μM of primers (Supplementary Data,
Table 3) and conditions: 95 °C for 10 min, 5 cycles (95 °C, 30 s; 62 °C,
45 s; 72 °C, 45 s), 50 cycles (95 °C, 30 s; 58 °C, 30 s; 72 °C, 90 s); ﬁnal
extension 30 min, 61 °C. Sequencing was performed with BigDye
Terminator v3.1 (Applied Biosystems, Foster City, CA).Newly described exons were identiﬁed using PCR primers
designed basing on the THRB genomic sequence (ref.seq.:
NC_000003.10) and the most probable donor and acceptor splice
sites, predicted using NNSPLICE0.9 [20].2.6. Protein isolation
TRβ1: tissue sampleswere homogenized (buffer: 150 mMNaCl, 1%
Triton X-100, 50 mM Tris-HCl pH 8.0, protease inhibitor cocktail
(Sigma-Aldrich, Saint Louis, MO), and 0.5 mM PMSF), incubated for
2 h at 4 °C with shaking and centrifuged at 12,000 rpm for 20 min at
4 °C. Caki-2 cells were harvested 72 h after transfection with
precursor miRNA-204 (pre-miR-204) or scrambled microRNA,
washed once in PBS, and lysed in RIPA buffer (150 mM NaCl, 1%
NP40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris–HCl at pH 8,
2 mMEDTA) containing protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO) and 1 mM PMSF.
D1: samples were homogenized (buffer: 0.1 phosphate buffer pH
7.0, 1 mM EDTA, 10 mM DTT, 250 mM sucrose, protease inhibitor
cocktail (Sigma-Aldrich, St. Louis, MO), and 1 mM PMSF), and
centrifuged at 15,000 g for 30 min, at 4 °C. The supernatant was
centrifuged at 75,000g for 1.5 h at 4 °C. The microsome fraction pellet
resuspended in homogenization buffer.
Protein extracts were stored at −70 °C.2.7. Western blotting
40 μg of protein was resolved by 10% SDS-PAGE and transferred to
nitrocellulose membrane. Membranes were blocked overnight (8 °C,
5% non-fat milk in TBS-T buffer: 10 mM Tris-HCl, 150 mM NaCl, 0.1%
Tween-20; pH 7.6), washed three times in TBS-T for 10 min, and
incubated overnight at 8 °C with primary antibody diluted 1:1000 in
TBS-T buffer with 5% non-fat milk (anti- TRβ1 antibody: cat. no.
ab2744, Abcam plc, Cambridge, UK; anti-D1 serum [54], a kind gift of
T.J. Visser). After washing 3 times for 10 min, membranes were
incubated for 1 h at RT with horseradish peroxidase-conjugated goat
anti-mouse secondary antibody (1:10000, DakoCytomation, Glostrup,
Denmark) (TRβ1) or goat anti-rabbit secondary antibody (1:10000,
DakoCytomation, Glostrup, Denmark) (D1), and washed 3 times for
10 min. Proteins were detected using Supersignal West Pico Chemi-
luminescent Substrate (Pierce Biotechnology, Rockford, IL). Subse-
quently, membranes were stripped and incubated with anti-β-actin
antibody diluted 1:10000 (cat. no. ab6276, Abcam plc, Cambridge, UK)
in TBS-T buffer for 1 h, washed three times and used for detection.
Levels of TRβ1 and Dio proteins were normalized to β-actin
expression.2.8. Thyroid hormone levels in tissue samples
Intracellular T4 and T3 concentrations were measured by
radioimmunoassay following tissue extraction as described [17].2.9. Bioinformatic analysis
5′UTR secondary structures were predicted using RNAstructure 5.0
[18]. Splice site predictions were determined using NetGene2 Server
[19], and NNSPLICE 0.9 [20].
Identiﬁcation of miRNA target sites in the 3′UTR-1 was performed
using: RNAhybrid [21], PicTar [22], TargetScan 5.1 [23] and miRanda
[24].
Detailed descriptions of bioinformatic analyses are provided in
Supplementary Data.
Fig. 3. Expression of TRβ1 5′ and 3′UTR variants. Expression of 5′UTR variants A and F (Panel A), F1 (Panel B) and 3′UTR variants (Panel C) in paired tumor (T) and control tissue (C) and in
non-neoplastic kidney (N). Analysis of F1 expression revealed two groups of samples: onewith low levels (LL) of F1 (74% of samples) and onewith high levels (HL) of F1 in control tissues
C and N. The data are means±S.E. in HL samples and as median values with 95%CI in LL samples as data were not normally distributed in this group. Statistical analysis was performed
using paired t-test for variants A, F, F1 inHL samples, 3′UTR-1, and 3′UTR-2 orWilcoxon paired test for F1 in LL samples. Variant A: n=10 for N, n=37 for C, n=37 for T; variant F: n=10
for N,n=35 for C, n=35 for T; F1 LL samples: n=30 for C, n=30 for T; F1HL samples: n=10 for N, n=8 for C, n=8 for T; variant 3′UTR-1: n=10 for N, n=32 for C, n=32 for T, variant
3′UTR-2: n=30 for C, n=30 for T. ***pb0.001. **pb0.01.
999A. Master et al. / Biochimica et Biophysica Acta 1802 (2010) 995–10052.10. Statistical analysis
The Shapiro–Wilk test was used to determine normality of data
distribution. Normally distributed data were analyzed by paired t-testand non-parametric data by Wilcoxon matched pairs test. Data from
luciferase assays were analyzed by ANOVA followed by Dunnett's
multiple comparison test. pb0.05 was considered statistically
signiﬁcant.
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3.1. Identiﬁcation of new UTR splice variants
The previously described TRβ1 5′UTR variants A-G and variant
IVS4A encoding truncated protein [10] were expressed in benign and
malignant kidney tissue. Moreover, four new TRβ1 5′UTR variants
(A2, A3, F1, F2) were identiﬁed (Fig. 1B). Two variants, F1 and F2,
contained a previously unknown exon located between exons 1d and
1e, designated here as exon 1d1 (Fig. 1B). The new variants A2 and A3
were similar in structure to the previously described variant A but
contained an additional exon between exons 2a and 3. Variant A2
additionally contained exon 2b and variant A3 additionally contained
exon 2c. Finally, a new variant of IVS4A containing a fragment of
intron 4 was also identiﬁed and named IVS4B. Variant IVS4B, in
contrast to IVS4A, contained exon 1c and open reading frame (ORF)
that predicts expression of a 28 amino acid protein with a stop codon
located in intron 4.
The structure of TRβ1 3′UTR was less complex (Fig. 1C). The
previously described TRβ1 mRNA contains a 3′UTR sequence
designated here as 3′UTR-1. Sequencing revealed that 3′UTR-2 lacks
a 123 nucleotide region of exon 10 that is located between nucleotides
2272–2394. This region contains a putative binding site for miRNA-
204, located between nucleotides 2313–2319. The sequences of the
new UTR variants with splice consensus sites are shown in
Supplementary Data.
3.2. Reduced expression of TRβ1 mRNA and protein in ccRCC
Levels of TRβ1 mRNA were determined in ccRCC and control
tissues by real-time PCR using primers which ampliﬁed the 5′-end of
the TRβ1 coding sequence. TRβ1 mRNA expression was reduced by
70% in ccRCC tumor tissue (T) compared with paired control tissue
(C). There was no signiﬁcant difference in TRβ1 mRNA expression
between control samples (C) and (N) (Fig. 2A). Accordingly, TRβ1
protein expression was reduced by 91% or was undetectable in ccRCC
tissue compared with paired control samples (Fig. 2B). This 20%
difference in reduction of TRβ1 protein compared to mRNA in tumors
versus paired controls may result from aberrant post-transcriptional
regulation of TRβ1 protein expression in ccRCC. Thus, we analyzed
expression of the TRβ1 5′UTR variants and investigated expression of
miRNAs predicted to interact with the TRβ1 3′UTR.
3.3. Expression of TRβ1 UTRs in ccRCC
Expression of 5′UTR variants A, F, F1, as well as 3′UTR-1, 3′UTR-2
and the coding sequence of TRβ1 were analyzed by real-time PCR.
Variants, B-E, F2, G, A2 and A3 were either expressed at very low
levels or were undetectable in most samples and accurate quantiﬁ-
cation of their expression was not possible (data not shown).
Expression of 5′UTR variants A and F were reduced in tumors by
75% and 62%, respectively, compared to (C) control samples (Fig. 3A).
5′UTR variant A was expressed at the highest level in ccRCCs and their
controls (1.8–7.4 transcripts per 103 copies of ACTB1), whereas variant
F was expressed in all samples at very low levels (3–8 transcripts per
1013 copies of ACTB1). Expression of newly identiﬁed variant F1 (0.05–
172 transcripts per 106 copies of ACTB) was higher than expression of
variant F but lower than variant A. The expression proﬁle of variant F1
was complex, however, and two distinct groups of paired samplesFig. 4. Levels of miRNA-204 in tissues and its regulatory effect on TRβ1 expression. A. Po
RNAHybrid. miRNAs binding to 3′UTRs requires only partial complementarity to the target. N
expression in ccRCC tumor tissue (T). Data aremeans±S.E. (n=35 for T, n=35 for C, n=10
*pb0.05. C. miR-204 mediated downregulation of TRβ1 and its target gene D1 transcript in C
line transfected with pre-miR-204 or scrambled microRNA (negative control). Data are exp
compare cells transfected with pre-miR-204 and with scrambled microRNA. ***pb0.0001.W
with pre-miR-204 or scrambled pre-miR-204 (negative control). Cells were harvested 72 hwere deﬁned. In one group (n=8) there was a very high level of F1
expressed in controls compared to ccRCCs (HL, in Fig. 3B), whereas in
a second group, containing most of the tested pairs (n=30) F1
expression was much lower (LL, in Fig. 3B) and decreased by 90% in
paired tumor tissue. In the HL group, expression of F1 in ccRCC tissue
was almost undetectable. There was a signiﬁcantly (pb0.0001) higher
level of expression of F1 in N noncancerous samples from the LL group
compared to C normal control tissue (Fig. 3B). Expression of the
variants IVS4A and IVS4B was reduced by 99% in tumour (T)
compared to paired control (C) tissue although levels were much
higher in samples from non-malignant diseased kidneys (N) (Sup-
plementary Data, Fig. 1S).
Expression of the 3′UTR-1 and 3′UTR-2 variants was decreased by
79% and 86%, respectively, in tumors, compared to control samples
(Fig. 3C). 3′UTR-1 (2.3–11 transcripts per 103 copies of ACTB1) was
expressed at a similar level to 5′UTR variant A, whereas 3′UTR-2
expression was 1000-fold lower (0.8–5.7 transcripts per 106 copies of
ACTB1).
The levels of expression of the TRβ1 transcript containing the
coding sequence (ORF) of TRβ1 protein (2.0–7.7 transcripts per 103
copies of ACTBI) were similar to levels of the 5′UTR A and 3′UTR-1
variants (Figs. 2 and 3). Abundances of particular UTR variants relative
to the most highly expressed variant A are shown in Fig. 2S.
3.4. The expression of miRNA-204 regulating TRβ1 expression in ccRCC
Bioinformatic analysis of the TRβ1 mRNA 3′UTR identiﬁed
multiple potential miRNA binding sites, 14 of which were selected
for further analysis (Supplementary Data, Table 4) based on their
identiﬁcation by at least two of four independent bioinformatic
approaches. In preliminary studies we determined the relative
expression of 14 candidate miRNAs in paired control and ccRCC
tissue from two kidneys. These studies revealed differential expres-
sion of seven miRNAs: miRNA-1, miRNA-211, miRNA-204, miRNA-
206, miRNA-154, miRNA-335 and miRNA-512-3p. Subsequent anal-
ysis in 39 paired samples revealed that expression of miRNA-204 was
increased by 1.2- to 2.0-fold in ccRCC compared to paired control
tissue (Fig. 4), whereas expression of the six other candidate miRNAs
did not differ signiﬁcantly between ccRCC and control tissue (data not
shown). The predicted miRNA binding site for miRNA-204 was
located in the 61 bp region of exon 10 that was present in 3′UTR-1 but
absent from 3′UTR-2 (Figs. 1C and 4A).
In order to test whether miR-204 is a true TRβ1 regulator, Caki-2
cells were transfected with miR-204 precursor and scrambled control.
Subsequent real-time PCR and Western blot analysis of TRβ1, as well
as real-time PCR of TRβ1 dependent gene, DIO1 were performed.
Transfection with miR-204 precursor resulted in a large (three
magnitudes of order) induction of miR-204 expression (Fig. 3S. in
Supplementary Data) which was followed by ~42% decrease of TRβ1
mRNA expression and ~35% decrease of DIO1mRNA expression when
compared with scrambled control. Moreover, the protein expression
of TRβ1 is also almost twice lower in pre-miR-204 transfected cells in
comparison with scrambled control (Fig. 4).
3.5. TRβ1 5′UTR variants inﬂuence protein translation efﬁciency in
ccRCC cells
To analyze the effect of the TRβ1 5′UTR variants A-G and new
variant F1 on translation efﬁciency, ccRCC derived Caki-2 cells weresitions of potential miRNA binding sites in TRβ1 3′UTR identiﬁed by TargetScan and
ucleotides of perfect complementarity are shown as seedmatch. B. IncreasedmiRNA204
for N). Statistical analysis was performed using paired t-test to compare C and T samples.
aki-2 cell line. Semi-quantitative real-time PCR assay for TRβ1 and D1 in the Caki-2 cell
ressed as mean values±SEM. Statistical analysis was performed using paired t-test to
estern blotting for TRβ1 and β-actin (loading control) in the Caki-2 cell line transfected
after transfection; the relative density of bands was quantiﬁed by densitometry.
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Fig. 5. Expression of DIO1 and tissue concentrations of thyroid hormones in ccRCC. A.
Expression of DIO1mRNA in tissue samples. n=33 for T, n=33 for C, n=10 for N. Data are
means±S.E, ***pb0.001. Statistical analysis was performed using a paired t-test. B. Western
blot showing expression of D1 (28 kDa protein) and β-actin (42 kDa protein) in four
representative C and Tpaired samples. C. Tissue concentrations of T4 and T3, in paired control
(C) and ccRCC (T) samples. Data are shown as mean±S.E. (n=12 for T, n=12 for C).
Statistical analysis was performed using paired t-test. ***pb0.001.
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determined. In ccRCC Caki-2 cells, inclusion of 5′UTR variant A
(folding free energy ΔG=−69.0 kcal/mol), resulted in the highest
degree of luciferase activity when compared to other 5′UTR variants
(Supplementary Data, Fig. 4S.A). By contrast, variant F1 (ΔG=
−124.4 kcal/mol) exerted the strongest inhibitory effect on luciferase
expression, decreasing activity by more than 98% comparing to
activity of the control vector lacking a TRβ1 5′UTR.
To check whether the presence of TRβ1 ORF inﬂuences the
regulatory effect of UTR on translational efﬁciency, we performed an
in vitro experiment using pKS-derived plasmids (Fig. 4S.B). To do this,
luciferase transcription and translation rates from construct UTR-A+
TRβ1ORF+Luc were tested in in vitro transcription/translation assay
together with the following constructs: UTR-A+Luc; TRβ1ORF+Luc;
Control. These assays revealed that: (1) there were no differences
between transcriptional efﬁciency of control and none of the
constructs; (2) translational efﬁciency of TRβ1ORF+Luc did not
statistically signiﬁcantly differ when compared with control; (3)
translational efﬁciency of UTR-A+Luc was 22% lower when compared
to control (pb0.01); (4) translational efﬁciency of UTR-A+TRβ1ORF+Luc was 28% lower when compared to control (pb0.01); 5) there was
no statistically signiﬁcant difference between translational efﬁciency of
UTR-A+Luc and UTR-A+TRβ1ORF+Luc. Thus, we concluded that
TRβ1ORF did not inﬂuence the regulatory effect of 5′UTR A on
translational efﬁciency.
The prediction of secondary structures formed by the 5′UTRs
revealed that the variants A2, A3, F1, and F2 fold into structures of
different free energies. Variant F2 formed the most stable secondary
structure (ΔG=−171.0 kcal/mol) and variant A3 was the least stable
(ΔG=−86.6 kcal/mol) (Supplementary Data, Table 5 and Fig. 5S–9S).
3.6. Reduced expression of the TRβ1 target gene, DIO1, in ccRCC
The promoter of type 1 iodothyronine deiodinase (DIO1) was
shown to be bound in vitro by both thyroid hormone receptors: TRα
and TRβ [25]. It was also suggested, however, that in the kidney DIO1
expression is solely activated by TRβ1 [26]. In addition, our
unpublished results of experiments performed on the material used
in this study show lack of changes between the expression of TRα1 in
ccRCC tissues in comparison with control samples. Therefore we
assumed that DIO1 expression would be a good marker of changes of
TRβ1 level in kidney samples. To determine whether decreased
expression of TRβ1 mRNA and protein observed in ccRCC was
accompanied by changes in T3-target gene expression, we analyzed
expression of DIO1 in eleven paired samples of ccRCC and normal
kidney tissue. In accordance with the reduced TRβ1 expression in
ccRCC, DIO1mRNAwas decreased by 92% in tumor tissue compared to
normal (Fig. 5A) and D1 protein was undetectable in tumors but
detectable in samples of paired normal tissue (Fig. 5B).
3.7. Tissue T3 concentrations are reduced in ccRCC compared with
normal kidney
TRβ1 regulates target gene expression in response to T3, whereas
T4 does not bind and activate the receptor at physiological
concentrations. T4 is a pro-hormone that is converted to T3 by the
type 1 and 2 deiodinase enzymes, of which DIO1 gene is regulated
directly by T3 whereas DIO2 is not [27]. Thus, the level of deiodinase
activity determines the intracellular level of T3 available to bind and
activate TRs. In order to determine whether reduced expression of
DIO1 correlated with reduced tissue T3 concentration, the levels of T4
and T3 were determined in 11 paired ccRCC and normal kidney tissue
samples. The level of T4 did not differ between normal and ccRCC
tissue, whereas the concentration of T3 was reduced by 58% in ccRCC
tissue (Fig. 5C).
4. Discussion
These studies demonstrate reduced TRβ1 mRNA and protein
expression in human ccRCC (Fig. 2). We found discordance in the
magnitude of the change in TRβ1 mRNA level (70% reduction in
ccRCC) compared to protein (91% reduction). These results conﬁrm
our previous ﬁndings achieved by different mRNA analysis method
(Northern blot) and different antibodies as well as Western blot
protocol and in different tissue samples [28]. These repeatedly
obtained, coherent results suggest that TRβ1 expression is subject to
posttranscriptional regulation in ccRCC. Reduced TRβ1 expression in
ccRCC was accompanied by absent D1 protein and a 58% reduction in
tissue T3 concentration (Fig. 5). The current ﬁndings are consistent
with previous ﬁndings of abnormal TRβ1 expression [4] and reduced
D1 activity [29] in renal cancer. Taken together, the data provide
powerful evidence of tissue hypothyroidism and impaired T3 action in
ccRCC that is maintained by reduced expression of TRβ1 and D1
(Fig. 6).
Previous studies have shown that TRβ1 mRNA 5′UTR undergoes
complex alternative splicing, and eight 5′UTR variants that regulate
Fig. 6.Mechanisms of aberrant TRβ1 action in ccRCC. Disruption of TRβ1 activity may result from loss of heterozygosity (LOH) at the THRB locus [51] and several other mechanisms:
(1a) reduced TRβ1 expression, (1b), decreased intracellular T3 concentrations, (2) mutations of TRβ1 (triangles) that inhibit binding of T3, (3) DNA [6], or (4) altering interactions
with coregulators [52]. Mechanisms that contribute to reduced TRβ1 expression include: (5) aberrant splicing and expression of TRβ1 UTRs, (6) increased expression of miRNAs that
interact with the TRβ1 3′UTR and (7) increased expression of the TRβ1 target gene DIO1, which results in reduced intracellular T3. The arrows accompanying the percentages show
the decrease of expression.
1003A. Master et al. / Biochimica et Biophysica Acta 1802 (2010) 995–1005efﬁciency of TRβ1 protein translation in a tissue-speciﬁc manner were
identiﬁed [10]. In the current studies we show that these variants are
expressed in normal kidney and ccRCC, and also identify 4 additional
5′UTR variants, a new 5′ variant that is predicted to encode a
truncated TRβ1 protein and a new 3′UTR variant that lacks a 123
nucleotide region containing putative miRNA binding sites (Fig. 1).
Detailed analysis demonstrated that 5′UTR variant A and 3′UTR-1
are expressed at similar levels to each other and to mRNA containing
the TRβ1 protein ORF, indicating the major TRβ1 coding mRNA
expressed in kidney and ccRCC contains 5′UTR A and 3′UTR-1.
Expression of all TRβ1 UTRs was reduced in ccRCC by between 62%
and more than 90% (Fig. 3). Differences in the ratios of the various
TRβ1 transcripts in healthy tissue compared to tumor suggests that
alternative splicing of TRβ1 UTRs is perturbed in ccRCC, as shown
previously for DIO1 in ccRCC [30]. Accordingly, aberrant alternative
splicing of other genes has been reported to contribute to carcino-
genesis in ccRCC [31–33]. Thus, the loss of transcripts F1 and IVS4B
that were undetectable in ccRCC tissue, and the absence of D1 protein
may represent new markers of tumor progression in ccRCC.
Interestingly, ccRCC-speciﬁc loss of D1 protein is in agreement with
our previous paper, concerning disturbed alternative splicing of DIO1
[30]. In that paper we suggested that alternative splicing of DIO1 in
ccRCC is “shifted” and leads to production of splice variants containing
premature termination codons (PTC) that may be degraded by
nonsense-mediated mRNA decay mechanism (NMD). Thus, ccRCC-
speciﬁc decrease of D1 protein would result not only from lowered
transcription rate but also from inhibition of translation due to NMD
of PTC containing splice variants.
The discordance between changes in levels of TRβ1 mRNA and
protein in ccRCC is suggestive of altered posttranscriptional regulation
of TRβ1 that may be mediated by alternative splicing of the 5′ and 3′
UTRs. The major TRβ1 transcript expressed in ccRCC contained 5′UTRvariant A and 3′UTR-1. Analysis of the effects of 5′UTR variants on
protein expression in Caki-2 renal cancer cells indicated that variant A
permitted the highest level of protein expression (Supplementary
Data, Fig. 4S) and was consistent with previous ﬁndings in JEG-3
choriocarcinoma cells [10]. The least efﬁciently translated 5′UTR
variant was F1 (Fig. 4S.). As this variant revealed also the largest
decrease of expression it could suggest an increase in TRβ1 protein
expression, rather than the decrease that we actually observed. It
must be noted however that both in control and tumor tissues the
expression of F1 was three orders of magnitude lower than expression
of the most efﬁciently translated variant A. Thus, the predicted the
impact of F1 on the ﬁnal level of TRβ1 protein is possibly rather low.
A small number of mRNAs possess long 5′UTRs of complex
secondary structure that contain upstream ORFs which inhibit protein
translation. However, if such 5′UTRs also contain internal ribosome
entry sites (IRES) and conditions favor IRES-dependent translation
these sequences can allow efﬁcient protein expression, thereby
demonstrating that 5′UTR sequence and secondary structure mediate
posttranscriptional regulation of gene expression [34]. Secondary
structure analysis of 5′UTR variant A revealed complex mRNA folding,
the presence of four upstream AUG translation initiation sites and two
putative IRES sequences (Supplementary Data, Fig. 5S), indicating
features that may provide a mechanism whereby variant A regulates
TRβ1 protein expression. The role of other minor TRβ1 5′UTR variants
in determining the total level of TRβ1 protein expressed in ccRCC,
however, remains to be elucidated. For example, although variant D
was expressed at very low levels in ccRCC, previous studies have
shown it permits efﬁcient protein expression in kidney-derived COS-7
cells [10]. In this context, evidence supports a role for two possible
mechanisms of translation initiation: by non-classical, hypoxia-
induced, IRES-dependent (cap-independent) translation or by cap-
dependent protein synthesis in conditions where increased
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translation from pools of mRNAs containing 5′UTRs with complex
secondary structure [35]. Although the functional signiﬁcance of
alternative splicing of the TRβ1 5′UTR in ccRCC is currently unknown,
aberrant expression of alternative 5′UTRs has been shown to
contribute to carcinogenesis mediated by tumor suppressors
[12,36], and oncogenes [37]. In the light of the complex secondary
structures of low copy number TRβ1 5′UTRs and evidence for selective
translation of structured mRNAs in aggressive metastatic cancer or
oxygen deprived tumors [35] it is likely that the 5′UTR of TRβ1 plays
an important role in controlling levels of receptor protein in ccRCC
and this may inﬂuence tumor progression.
In addition to the role of the 5′UTR, alternative splicing of the 3′
UTR is likely to be important. Analysis of the main TRβ1 3′UTR variant
(3′UTR-1) identiﬁed miRNA-204 as a candidate regulator of TRβ1
expression. A binding site for miRNA-204 was identiﬁed in TRβ1 3′
UTR-1 but not in the minor 3′UTR-2 splice variant and miRNA-204
expression was found to be increased 2-fold in ccRCC (Fig. 4).
Moreover, as we showed, overexpression of miR-204 in Caki-2 cells
leads to downregulation of TRβ1 mRNA and protein. These ﬁndings
are consistent with studies indicating that miRNA-204 acts as an
inhibitor of mRNA expression [38].
Apart from TRβ1, another TR isoform is present in the kidney,
TRα1, which has been also shown to bind the promoter of DIO1 gene
in vitro [25]. It was suggested, however, that DIO1 expression in the
kidney is solely activated by TRβ1 [26]. In addition, our unpublished
results of experiments performed on the material used in this study
show that expression of TRα1 does not change in ccRCC when
compared control samples. Finally, miR-204-mediated downregula-
tion of TRβ1 in Caki-2 cells is accompanied by decrease of DIO1mRNA
expression, what additionally conﬁrms the linkage between changes
in TRβ1 and DIO1 expression in the kidney.
The biological signiﬁcance of our ﬁndings comes from emerging
evidence demonstrating that TRβ1 functions as a tumor suppressor
[39–41]. Its role is complex, however, as the T3-dependent activity of
TRβ1 may have a biphasic effect on cell growth and proliferation.
Knockout mice lacking TRβ1 show delayed hepatocyte proliferation
and enhanced apoptosis in response to partial hepatectomy [42] and
tumor cell growth is retarded in hypothyroid mice [39]. On the other
hand, the phenotype of tumors induced in hypothyroid hosts is more
mesenchymal, and their invasiveness and metastatic behaviour are
enhanced [39]. These ﬁndings are in line with previous reports
documenting reduced tissue T3 in human gliomas [43] and demon-
strating an association between the low T3 syndrome and renal cancer
[44], although decreased concentrations of T3 have also been shown
to reduce proliferation of Caki-2 cells in vitro [45]. Interestingly,
variations in T3 and TRs level may directly initiate changes in activity
of other target genes with direct effect on proliferation including
those engaged in the regulation of cell cycle progression. An example
of such a gene is E2F1, a transcription factor controlling G1 to S phase
transitionwhose expression is negatively regulated by TRs [46]. As we
showed, the expression of E2F1 is increased in renal cancer tissues,
and this is in agreement with disturbed function of TRs [47]. E2F1 is
known to regulate cellular proliferation [48] therefore its disturbed
expressionmay contribute to ccRCC carcinogenesis. Moreover, Liu et al.
[49] showed that CD74 induced tumorigenesis of ccRCC is mediated by
PI3K/AKT pathway and it is known that this pathway is regulated by
TRβ1/T3 [50]. Thus, it is highly probable that disturbances of TRβ1 and
T3 observed in this study may initiate wide net of changes in multiple
target genes, causing direct effect on proliferation.
In summary, we demonstrate that reduced expression of TRβ1 in
ccRCC is likely to be maintained by posttranscriptional mechanisms
mediated by alternative splicing of the TRβ1mRNA 5′ and 3′UTRs along
with increased expression of miRNA-204. Reduced expression of TRβ1
results in tissue T3 deﬁciency mediated by inhibition of D1 expression.
The recently identiﬁed tumor suppressor activity of TRβ1 [39–41]indicates that reduced TRβ1 expression and tissue hypothyroidism in
ccRCC tumors may be involved in the process of carcinogenesis itself or
in maintaining a proliferative advantage to the malignant cells.
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